Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose esketamine for postoperative depressive status and immune function in acoustic neuroma surgery
ChiCTR2400084537Phase 4Recruiting
- Sponsor
- Shandong Second Provincial General Hospital
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in acoustic neuroma and major depressive disorder (MDD) (2 arms), sponsored by Shandong Second Provincial General Hospital. Primary endpoint: Incidence of postoperative depressive state. Started Jan 2024; status: recruiting.
02
Drugs
esketamine
03
Conditions
acoustic neuromamajor depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2400084537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084537.